Aminoguanidine inhibits aortic hydrogen peroxide production, VSMC NOX activity and hypercontractility in diabetic mice

Jeong-Ho Oak1,2, Ji-Youn Youn1,2 and Hua Cai*1,2

Address: 1Department of Anesthesiology, David Geffen School of Medicine at University of California Los Angeles (UCLA), Los Angeles, CA, USA and 2Department Medicine, David Geffen School of Medicine at University of California Los Angeles (UCLA), Los Angeles, CA, USA

Email: Jeong-Ho Oak - Oak_Jeong-ho@takeda.co.jp; Ji-Youn Youn - jyyoun@ucla.edu; Hua Cai* - hcai@mednet.ucla.edu

* Corresponding author

Abstract

Background: Dysfunctionally uncoupled endothelial nitric oxide synthase (eNOS) is involved in producing reactive oxygen species (ROS) in the diabetic endothelium. The present study investigated whether anti-diabetes drug Aminoguanidine (AG) has any effect on eNOS function and vascular oxidant stress.

Methods and Results: Blood glucose levels were increased to 452.0 ± 15.1 mg/dl in STZ-treated male C57BL/6J mice (148.4 ± 3.2 mg/dl in untreated controls). Aortic productions of NO• and O2•− were measured specifically and sensitively using electron spin resonance. Diabetic mice had a marked increase in aortic O2•− production. Aortic hydrogen peroxide (H2O2) production was also increased in diabetic aortas and significantly attenuated by AG. AG however had only a marginal effect in reducing aortic O2•− production, which corresponded to a minimal effect in improving aortic nitric oxide (NO•) bioavailability. The endothelium-dependent vasodilatation however was modestly but significantly improved by AG, likely consequent to AG-induced reduction in hypercontractility. NAD(P)H oxidase (NOX)-dependent O2•− production was completely attenuated by AG in endothelium-denuded diabetic aortas.

Conclusion: In summary, despite that AG is not an effective eNOS recoupling agent presumably consequent to its ineffectiveness in preventing endothelial NOX activation, it is inhibitory of aortic H2O2 production, VSMC NOX activity, and hypercontractility in diabetes.

Background

Cardiovascular complications are the primary causes of mortality in diabetic patients [1,2]. Accumulating evidence has demonstrated that increased production of reactive oxygen species (ROS) contributes to etiology of diabetes [3-6] and its cardiovascular complications [4,6-11]. Various enzymatic systems have been shown responsible for diabetic oxidant stress, including xanthine oxidase [12], NAD(P)H oxidase [13,14], and the more recently established, uncoupled endothelial nitric oxide synthase (eNOS) [15,16]. Oxidant stress contributes to diabetic vascular damages by acceleration of advanced glycation end products (AGEs) formation, modulation of extracellular matrix proteins, promotion of cell proliferation and migration, stimulation of kinases and proinflammatory proteins, and importantly, inactivation of nitric oxide (NO•), all of which are closely associated with the pathogenesis of diabetic vascular complications [17,18].
Aminoguanidine (AG) is one of the most extensively used inhibitors of AGEs accumulation. Beneficial effects in preventing cardiovascular events in diabetic rats have been observed with AG treatment, likely attributed to its effects on stopping AGE formation [19]. Besides its inhibitory action on AGE formation, AG acts as a competitive and selective inhibitor for inducible nitric oxide synthase (iNOS) [20]. This action of AG has been known to be associated with reduction of peroxinitrite (ONOO⁻), which has deleterious roles in inducing NO* deficiency and cellular damages through degradation of eNOS cofactor, and inductions of inflammation, lipid peroxidation, protein nitrosylation and DNA fragmentation [18,21,22]. Previous investigations have also demonstrated that AG reduced hydrogen peroxide (H₂O₂) induced intracellular hydroxyl radical formation and apoptosis, further demonstrating a potential antioxidant activity [23,24]. These multiple actions of AG may improve endothelial function in diabetes independent of its AGE-inhibiting activity [22,23]. Apart from its beneficial effects, high dose of AG is associated with some adverse effects such as autoimmune symptoms, abnormal liver function, gastrointestinal disturbance, and flu-like symptoms [25,26]. These side effects are likely related to its structural similarities to hydrazine, an inducing factor of lupus like syndrome, and L-arginine, a substrate of NO* synthase [27]. Thus the potential effect of AG is complex in diabetes associated cardiovascular complication. The direct impact of AG on aortic oxidant stress and eNOS function is completely unknown despite that AG was found to suppress superoxide (O₂⁻) production, mitochondrial complex III activity and eNOS uncoupling in the kidney [26,28].

Therefore, in the present study we treated STZ-induced diabetic mice in vivo with AG, and measured aortic O₂⁻* and NO* productions by electron spin resonance (ESR) sensitively and specifically. AG only marginally reduced total aortic O₂⁻* production although it significantly attenuated aortic hydrogen peroxide (H₂O₂) generation. Endothelium-dependent vasodilatation was modestly yet significantly improved which was accompanied by AG-dependent significant reduction in aortic hypercontractility. NAD(P)H oxidase (NOX)-dependent O₂⁻* production in endothelium-denuded aortas was significantly attenuated by AG, likely contributing to the reduction in phenylephrine (PE)-induced hypercontractility. These data seem to implicate that although AG is ineffective in recoupling eNOS in diabetic aortas, it reduces vascular H₂O₂ production and hypercontractility in diabetes, which may in part account for its beneficial effects in preventing vascular disease development.

Methods

Diabetic mice and drug interventions
Male C57BL/6J mice (6-8 weeks old) were obtained from Jackson Laboratories. Mice were housed in a pathogen-free condition. The Institutional Animal Care and Usage Committee at the University of Chicago and University of California Los Angeles approved the use of animals and experimental procedures. Diabetes was induced by tail vein injection of Streptozocin (STZ, 100 mg/Kg) dissolved in 50 µL of 0.9% saline immediately before use, once a day for three days [15,29,30]. Blood glucose was determined using the One Touch Ultra® blood glucose meter (Lifescan) at baseline and on day four post STZ injection for each individual mouse. On day four, STZ diabetic mice were injected with Aminoguanidine (AG) [31] dissolved in 0.9% saline via tail vein at 100 mg/kg/day for three days. By day seven, animals were sacrificed using CO₂ inhalation and whole aorta was removed, cleared from surrounding connective tissues and cut transversely into 2 mm or 3 mm rings for subsequent experiments. Nitric oxide production and vasoreactivity measurement was performed with 2 mm of aorta segments and determination of superoxide and hydrogen peroxide level was conducted with each 3 mm of aorta. This model of diabetes is characterized by acute hyperglycemia. No renal dysfunction occurs during the study period of seven days [32].

Electron spin resonance measurement of aortic superoxide production

Freshly isolated aortas were placed into chilled modified Krebs/HEPES buffer (composition in mmol/L: 99.01 NaCl, 4.69 KCl, 2.50 CaCl₂, 1.20 MgSO₄, 1.03 KH₂PO₄, 25.0 NaHCO₃, 20.0 Na-HEPES, and 5.6 glucose [pH 7.4]), cleaned of excessive adventitial tissue, with care taken not to injure the endothelium. The specific O₂⁻* spin trap methoxycarbonyl-2,2,5,5-tetramethyl-pyrroline (CMH, 500 µmol/L, Alexis) solution was prepared freshly in nitrogen gas bubbled Krebs/HEPES buffer containing diethylthiocarbamic acid (DETc, 5 µmol/L Sigma) and deferoxamine (25 µmol/L, Sigma). Aortic segment (~3 mm) was then mixed with the spin trap solution and loaded into glass capillary (Fisher Scientific) for analysis of O₂⁻* signal (CM* formed after trapping O₂⁻*) using the electron spin resonance (ESR) spectrometer (Miniscope MS200, Magnettech, Germany). Some of the intact or endothelium-denuded aortic segments were incubated in presence or absence of NSC23766 (200 nmol/L, 90 min) to detect NOX sensitive superoxide production. The ESR settings used were bio-field, 3350; field sweep, 45.00 G (1 G = 0.1 mT); microwave frequency, 9.78 GHz; microwave power 7 dB (20 mW); modulation amplitude, 3000 mG; 4,096 points of resolution; and receiver gain, 700.

Amplex-Red assay for hydrogen peroxide production

Freshly isolated aortic rings (4 × 2 mm) were used for assessment of H₂O₂ production using a fluorometric horseradish peroxidase assay (Amplex-Red assay, Molecular Probes). Fluorescence was measured (excitation 530 nm and emission 590 nm) after 1 hour incubation at 37°C in dark against background fluorescence of buffer. Polyethylene glycol conjugated catalase (PEG-CAT, 300

http://www.cardiab.com/content/8/1/65
U/ml, Sigma)-inhibitable fraction reflects specific H$_2$O$_2$ signal. The rate of H$_2$O$_2$ production was presented as pmol/mg protein/min after calculation according to a standard curve generated using fresh H$_2$O$_2$ in reaction buffer [33].

**Electron spin resonance of aortic nitric oxide production**

Freshly isolated aortic rings (6 × 2 mm) were incubated with freshly prepared NO-specific spin trap Fe$_2^+$(DETC)$_2$ (0.5 mmol/L) in modified Kreb’s HEPES buffer (KHB) at 37°C for 60 min [spin trap and buffer recipe see above and previous publication [34], in the presence or absence of calcium ionophore A23187 (10 μmol/L). After the incubation, the aorta in KHB was snap-frozen in liquid nitrogen and loaded into a finger Dewar for analysis with ESR spectrophotometer. The instrument settings were as the followings: bio-field, 3280; field sweep, 77.54 G (1 G = 0.1 mT); microwave frequency, 9.78 GHz; microwave power, 4 dB (40 mW); modulation amplitude, 10 G; 4,096 points of resolution; and receiver gain, 900.

**Assessment of vascular reactivity**

Freshly prepared aortic rings (2 mm) were placed in organ baths containing modified Kreb’s HEPES buffer (recipe see above), aerated with a mixture of 95% oxygen/5% carbon dioxide and maintained at 37°C. After being kept under 5 mN tension for 90 min to stabilize, cumulative tension was measured by a Graz Tissue Bath System (Hugo Sachs Elektronik/ Harvard Apparatus GmbH, March Hugstetten, Germany) connected to a The MP100 workstations (BioPac Systems). Relaxation curve to acetylcholine (10$^{-9}$ to 10$^{-6}$ M) were assessed in aortic segment after contraction by phenylephrine (PE, 5 μmol/L). Data acquisition process and post-acquisition calculations were performed with AcqKnowledge software (BioPac Systems).

**Statistical analysis**

Differences among different groups of means were compared with unpaired t-test for two means and ANOVA for multiple means. Statistical significance was set for p < 0.05. All grouped data shown in the figures were presented as mean ± SEM.

**Results**

**Effect of Aminoguanidine on hyperglycemia**

Diabetic mice were created by streptozotocin (STZ) administration. On day of harvest (7-8th day after initial STZ injection, same hereafter), Blood glucose was elevated to 452.0 ± 15.1 mg/dl in diabetic mice vs 148.4 ± 3.2 mg/dl in the C57BL6 controls. AG (100 mg/kg/day, same hereafter) treatment since day 4 had no significant effect on STZ induction of hyperglycemia (data not shown).

**Effect of Aminoguanidine on aortic superoxide production**

Aortic production of O$_2^{-}$, detected specifically by electron spin resonance (ESR) and a cell-permeable specific spin trap, was more than doubled in diabetic mice (control vs diabetics: 3.3 ± 1.6 vs 7.0 ± 2.6 nmol/L per min per mg wet weight of aorta, p < 0.05). AG attenuated this response however marginally and insignificantly, as demonstrated by both representative ESR spectra and grouped data (Figs. 1A&B).

**Effect of Aminoguanidine on aortic hydrogen peroxide production**

Aortic H$_2$O$_2$ was detected specifically using an Amplex Red Assay (details see Methods section). Diabetic mice had a more than 4-fold increase in H$_2$O$_2$ production (5.86 ± 1.21 vs 22.39 ± 3.61 pmol/mg protein/min for control vs diabetics), which was significantly attenuated by treatment with AG (9.77 ± 4.71 pmol/mg protein/min, Fig. 2A, p < 0.05).
Aminoguanidine failed to restore aortic NO• production
Aortic NO• production was directly and characteristically detected using ESR. As shown in representative ESR spectra and grouped data (Figs. 3A&B), diabetic mice had markedly reduced bioavailable NO• (0.50 ± 0.08 in diabetics vs 0.72 ± 0.10 nmol/mg dry weight) and this response was however not significantly affected by treatment with AG (0.55 ± 0.15 nmol/mg dry weight). This result indicated that AG was ineffective in fully restoring eNOS function.

Aminoguanidine partially restored endothelium-dependent vasorelaxation: Role of attenuation of hypercontractility?
Interestingly, although AG did not protect NO• bioavailability likely due to its insignificance in reducing O2•- production from eNOS, AG partially yet significantly restored endothelium-dependent vasorelaxation (Fig. 4A). Intriguingly, diabetic aortas exerted a more than 3-fold increase in basal contractility in response to PE, which was markedly attenuated by AG (Fig. 4B). Vascular smooth muscle cell (VSMC) production of O2•- has been implicated in the hypercontractile response in diabetic blood vessels [35,36]. Furthermore, the source of this O2•- production could be NAD(P)H oxidase (NOX) [35]. Previously we have successfully measured O2•- production from endothelium-denuded vessels in the presence of NOX inhibitor. As shown in Fig. 5, consistent to previous findings, NOX remained active in VSMC [16]. AG completely diminished NSC23766-sensitive O2•- production, indicating that attenuation of NOX may have accounted for reduced hypercontractility observed with AG, which was further linked to improved vasorelaxation.

It is important to emphasize that in the intact endothelium, uncoupled eNOS is the primary source of ROS production 7 days after STZ injection [16]. This is presumably consequent to a transient activation of endothelial NOX based on our in vitro data from cultured aortic endothelial cells [34]. In this earlier study we found that, via transient activation endothelial NOX, angiotensin II (Ang II) induces H2O2 dependent eNOS uncoupling. Indeed, we found that in vivo treatment with Ang II signaling attenuators candesartan or captopril completely prevented eNOS uncoupling in diabetes [16].

We also found that after removal of endothelium to allow sufficient spin trap penetration to the underneath VSMC, NOX-dependent O2•- production remained elevated by day 7, which was found attenuated by candesartan or captopril previously, and now by AG. Therefore we believe that although AG may not have any effects on the endothelial NOX isoform in contrast to the Ang II attenuators, it is effective in inhibiting the VSMC NOX isoform. We are working on follow-up studies to identify cell-specific NOX isoforms that are involved in the eNOS uncoupling and NOX activation in diabetic endothelial cells and VSMC. These would be however beyond the scope of the present study.

Discussion
The present study systematically studied effects of AG on vascular oxidant stress, eNOS function and endothelium-
dependent vasorelaxation. Whereas AG only partially reduced vascular O$_2^•$ production, it attenuated H$_2$O$_2$ production significantly and improved endothelium-dependent vasodilatation, likely via a reduction in NOX-linked hypercontractility. Although AG does not seem to be an effective eNOS recoupling agent like Ang II signaling attenuators [16], it may still exert beneficial effects via attenuating VSMC NOX activity and H$_2$O$_2$ production.

Oxidant stress has been implicated in micro and macrovascular complication of diabetes [37]. Moreover, excessive generation of O$_2^•$ in endothelium by hyperglycemia has been considered one of the major factors involved in accelerating vascular complications. Recent studies have shown that eNOS uncoupling is the primary source of O$_2^•$ production in the diabetic endothelium [15,16], whereas NAD(P)H oxidase remain active in sub-endothelial VSMC [16]. eNOS uncoupling is a phenomenon whereby the enzyme generates O$_2^•$ rather than NO. Previously we established that increased O$_2^•$ production in STZ-induced diabetic mice is attributed to eNOS uncoupling, which was significantly attenuated by Ang II signaling blockers [16]. In the present study we examined effects of AGE chain breaker AG in recoupling eNOS and found AG failed to significantly reduce aortic O$_2^•$ production in diabetes. AG also failed to significantly restore aortic NO production however, remain unclear.

Despite lack of significant impacts on O$_2^•$/NO pathway, AG significantly attenuated aortic H$_2$O$_2$ production in diabetic mice. It also significantly, though modestly, improved endothelium-dependent vasodilatation, which is likely consequent to a reduction in hypercontractility that is associated with attenuation of VSMC NOX activity. Ineffective eNOS recoupling agent that is, AG proved to be

**Figure 4**

Effects of AG on vascular reactivity. **A**: AG partially restored endothelium-dependent vasorelaxation. **B**: AG diminished diabetes induced aortic hypercontractility. Data are presented as mean ± SEM, n = 6.

**Figure 5**

Effects of AG on NOX-sensitive superoxide (O$_2^•$) production. **A**: NSC23766-sensitive O$_2^•$ production from intact aortas **B**: NSC23766-sensitive O$_2^•$ production from endothelium denuded aortas. Data are presented as mean ± SEM, n = 6.
highly effective in attenuating diabetes-induced aortic hypercontractility.

There have been controversial observations of diabetic hypercontractility given species, age, diabetic type, diabetic stage, and vessel types [14,39-43]. For instance, a recent study by Su et al., showed that acetylcholine dependent dilation was decreased in diabetes whereas there was no difference between control and diabetic group in response to PE, concluding no specific role of VSMC contraction in type 2 diabetes [14]. Not in agreement with our data, they observed that AG did not alter vasoconstriction to PE, indicating that AGE formation is not associated with muscle contraction in type 2 diabetic mesenteric arteries [14]. On the other hand, other studies demonstrated hypercontractility to PE in aortas of STZ-induced diabetes [44,45]. In agreement with our results, AG normalized the response to PE in STZ diabetic mice without affecting plasma glucose levels [44]. Taken together, our results are consistent with previous observations regarding effect of AG on vascular hypercontraction in conduit vessels of early stage type 1 diabetes, hence indicating a potential beneficial effect of AG for prevention of cardiovascular complication for this particular diabetic type and stage.

It has been hypothesized that the basal hypercontractility is dependent on O$_2^-$ in STZ induced diabetic mice [36]. In the denuded aortas of human diabetes, O$_2^-$ production was also found elevated [35]. Indeed we have observed that in the endothelium-denuded aorta, AG completely attenuated NOX dependent O$_2^-$ production from VSMC (Fig. 5). Theoretically this reduction in O$_2^-$ could feed back to the endothelium to partially contribute to preservation of NO bioavailability. On the other hand, loss of O$_2^-$ in VSMC may directly modulate VSMC contractility via undefined mechanisms. It is interesting to speculate that loss of NOX-derived O$_2^-$ in diabetic VSMC might underlie AG reduction of hypercontractility.

Conclusion

In summary, AG has been examined systematically for its effects on vascular oxidant stress, eNOS function and endothelium-dependent vasorelaxation. To our knowledge these are first endeavors. This agent was ineffective in reducing plasma glucose levels, partially effective in inhibiting total O$_2^-$, and insignificantly effective in improving NO bioavailability in diabetes. However, it reduced aortic H$_2$O$_2$ production and improved endothelium-dependent vasorelaxation while diminished hypercontractility of aortas. Whether this is attributed to AG-dependent significant reduction in VSMC NOX activity remains to be further elucidated.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

JHO collected data and performed data analysis. JYY participated in data analysis and manuscript preparation. HC designed the study and participated in data analysis and interpretation, and manuscript preparation. All authors have read and approved the final version of the manuscript.

Acknowledgements

The authors’ work is supported by National Heart, Lung and Blood Institute Grants HL-077440, HL-081571, an American Heart Association Grant 0435189N, an American Diabetes Association Award 7-04-RA-16, a Career Development Award from the Schweppe Foundation, and start-up funds from the University of Chicago and University of California Los Angeles (all to H. Cai).

References

1. Laing SP, Swerdlow AJ, Slater SD, Burden AC, Morris A, Waugh NR, Gatting W, Bingley PJ, Paterson AD, et al. Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes. Diabetologia 2003, 46(8):760-765.
2. Paterson AD, Rutledge BN, Cleary PA, Lachin JM, Crow RS. The effect of intensive diabetes treatment on resting heart rate in type 1 diabetes: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study. Diabetes Care 2007, 30(8):2107-2112.
3. Goth L, Eton JW: Hereditary catalase deficiencies and increased risk of diabetes. Lancet 2000, 356(9244):1810-1811.
4. Roatta P, Nawroth PP, King G, Möller W, Trischler HJ, Packer L. The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a Congress Series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society. Diabetes Metab Res Rev 2001, 17(3):189-212.
5. Sakai K, Matsumoto K, Nishikawa T, Suefuji M, Nakamaru K, Hirashima Y, Kawashima J, Shirotani T, Ichinose K, Brownlee M, et al.: Mitochondrial reactive oxygen species reduce insulin secretion by pancreatic beta-cells. Biochem Biophys Res Commun 2003, 300(1):216-222.
6. Ceriello A: New insights on oxidative stress and diabetic complications may lead to a “Causal” antioxidant therapy. Diabetes Care 2003, 26(5):1589-1596.
7. Schmidt AM, Yan SD, Wautier JL, Stern D. Activation of receptor for advanced glycation end products and lectin-like oxidized receptor 1. Diabetes 2003, 52(1):71-77.
8. Schmidt AM, Yan SD, Wautier JL, Stern D. Acute activation of AGE receptors and lectin-like oxidized receptor 1. Diabetes Metabolism 2003, 29(8):748-52.
9. Schmidt AM, Yan SD, Wautier JL, Stern D. Acute activation of AGE receptors and lectin-like oxidized receptor 1. Diabetes Metabolism 2003, 29(8):748-52.
10. Schmidt AM, Yan SD, Wautier JL, Stern D. Acute activation of AGE receptors and lectin-like oxidized receptor 1. Diabetes Metabolism 2003, 29(8):748-52.
11. Schmidt AM, Yan SD, Wautier JL, Stern D. Acute activation of AGE receptors and lectin-like oxidized receptor 1. Diabetes Metabolism 2003, 29(8):748-52.
12. Schmidt AM, Yan SD, Wautier JL, Stern D. Acute activation of AGE receptors and lectin-like oxidized receptor 1. Diabetes Metabolism 2003, 29(8):748-52.
13. Schmidt AM, Yan SD, Wautier JL, Stern D. Acute activation of AGE receptors and lectin-like oxidized receptor 1. Diabetes Metabolism 2003, 29(8):748-52.
tion in type 2 diabetic mice. Arterioscler Thromb Vasc Biol 2008, 28(8):1432-1438.
15. Hink U, Li H, Molnau H, Oelze M, Matthes E, Hartmann M, Skatchkov M, Thais F, Stahli RA, Warnholtz A, et al.: Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res 2001, 88(2):E14-22.
16. Oak JH, Cai H: Attenuation of angiotensin II signaling recouples eNOS and inhibits nonendothelial NOX activity in diabetic mice. Diabetes 2007, 56(1):118-126.
17. Johansen JS, Harris AK, Rychly DJ, Ergul A: Oxidative stress and the use of antioxidants in diabetes: linking basic science to clinical practice. Cardiovasc Diabetol 2005, 4(1):5.
18. Lorenzo MA, Gagliardi S, Nacci C, Carratu MR, Montagnani M: Endothelial dysfunction in diabetes: from mechanisms to therapeutic targets. Curr Med Chem 2009, 16(1):94-112.
19. Stadler K, Jeni V, Somogyi A, Jakus J: Beneficial effects of aminoguanidine on the cardiovascular system of diabetic rats. Diabetes Metab Res Rev 2007, 23(4):493-498.
20. Aka C, Karabulut AB, Kirimliglu H, Yilmaz M, Kirimliglu V, Yilmaz S: Protective effect of aminoguanidine against oxidative stress in an experimental porcine adhesion model. Ann Clin Lab Sci 2009, 39(1):64-70.
21. Chowdhury R, Poulsby YE, Scott JL: Effects of aminoguanidine on tissue oxygen species induced by hindlimb unloading in rats. Ann Clin Lab Sci 2009, 39(1):64-70.
22. Szabo C, Ferrer-Sueta G, Zingarelli B, Southan GJ, Salzman AL, Radi R: Mercaptoethylguanidine and guanidine inhibitors of nitric-oxide synthase react with peroxynitrite and protect against peroxynitrite-induced oxidative damage. J Biol Chem 1997, 272(14):9030-9036.
23. Ihm SH, Yoo JH, Park SW, Ihm J: Effect of aminoguanidine on lipid peroxidation in streptozotocin-induced diabetic rats. Metabolism 1999, 48(9):1411-1415.
24. Giordano I, Fard AK, Hatchell DL, Brownlee M: Aminoguanidine inhibits reactive oxygen species formation, lipid peroxidation, and oxidant-induced apoptosis. Diabetes 1998, 47(7):1141-1150.
25. Bolton WK, Castron DC, Williams ME, Adler SG, Appel GB, Cartwright K, Foiles PG, Freedman B, Raskin P, Ratner RE, et al.: Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am J Nephrol 2003, 23(1):189-196.
26. Thornalley PJ: Use of aminoguanidine (Pimagidine) to prevent the formation of advanced glycation endproducts. Arch Biochem Biophys 2003, 419(1):31-40.
27. Alderton WK, Cooper CE, Knowles RG: Nitric oxide synthases: structure, function and inhibition. Biochem J 2001, 357(1):593-615.
28. Rosca MG, Mustata TG, Kinter MT, Ozdemir AM, Kern TS, Szewda LI, Brownlee M, Monnier VM, Weiss MF: Glycation of mitochondrial proteins from diabetic rat kidney is associated with excess superoxide formation. Am J Physiol Renal Physiol 2005, 289(2):F420-430.
29. Kuttler B, Schneider E: Diabetes mellitus in mice induced by multiple subdiabetogenic doses of streptozotocin: age and sex dependence. Acta Bio Med Ger 1982, 41(12):1199-1202.
30. Rees DA, Alcalde IC: Animal models of diabetes mellitus. Diabet Med 2005, 22(4):359-370.
31. Shen KP, Lo YC, Yang RC, Liu HW, Chen IJ, Wu BN: Antioxidant engulfosnedi-A protects against lipopolysaccharide-induced hypotension, hyperglycaemia and cytokine immunoreactivity in rats and mice. Pharm Pharmacol 2005, 57(1):17-25.
32. Tay YC, Wang Y, Kairaitis L, Kairaitis V, Zhang C, Harris DC: Can murine diabetic nephropathy be separated from superimposed acute renal failure? Kidney Int 2004, 65(1):599-398.
33. Cai H, McNally JS, Weber M, Harrison DG: Oscillatory shear stress upregulation of endothelial nitric oxide synthase requires intracellular hydrogen peroxide and CaMKII. J Mol Cell Cardiol 2004, 37(1):121-125.
34. Chalupsky K, Cai H: Endothelial dihydrofolarate reductase: critical for nitric oxide bioavailability and role in angiotensin II uncoupling of endothelial nitric oxide synthase. Proc Natl Acad Sci USA 2005, 102(25):9056-9061.
35. Fleischhacker E, Esenbalu E, Spitaler M, Holzmann S, Krabfai B, Kostner GM, Graier WF: Human diabetes is associated with hyperreactivity of vascular smooth muscle cells due to altered subcellular Ca2+ distribution. Diabetes 1999, 48(6):1323-1330.
36. Chang KC, Chung SY, Chong WS, Suh JS, Kim SH, Noh HK, Seong BW, Ko HJ, Chang KW: Possible superoxide radical-induced alteration of vascular reactivity in aorta from streptozotocin-treated rats. J Pharmacol Exp Ther 1993, 266(2):992-1000.
37. El-Remessy AB, Abou-Mohamed G, Caldwell RW, Caldwell RB: High glucose-induced tyrosine nitration in endothelial cells: role of eNOS uncoupling and aldose reductase activation. Invest Ophthalmol Vis Sci 2003, 44(7):3135-3143.
38. Brooks BA, Heffernan S, Thomson S, McLennan SV, Twigg SM, Yue D: Effects of diabetes and aminoguanidine treatment on endothelial function in a primate model of type 1 diabetes. Am J Primatol 2008, 70(8):796-802.
39. Rodriguez-Manas L, Angulo J, Vallejo S, Peiro C, Sanchez-Ferrer A, Cercas E, Lopez-Doriga P, Sanchez-Ferrer CF: Early and intermediate Amadori glycosylation adds, oxidative stress, and endothelial dysfunction in the streptozotocin-induced diabetic rats vasculature. Diabetologia 2003, 46(4):556-566.
40. Pieper GM: Enhanced, unaltered and impaired nitric oxide-mediated endothelium-dependent relaxation in experimental diabetes mellitus: importance of disease duration. Diabetologia 1999, 42(2):204-213.
41. Hopfrner RL, McNeill IR, Gopalakrishnan V: Plasma endothelin levels and vascular responses at different temporal stages of streptozotocin diabetes. Eur J Pharmacol 1999, 374(2):221-227.
42. Schofield I, Malik R, Izzard A, Austin C, Heagerty A: Vascular structure and functional changes in type 2 diabetes mellitus: evidence for the roles of abnormal myogenic responsiveness and dyslipidemia. Circulation 2002, 106(24):3037-3043.
43. Baj G, Koller A, Kaley G: PPARgamma activation, by reducing oxidative stress, increases NO bioavailability in coronary arteries of mice with Type 2 diabetes. Am J Physiol Heart Circ Physiol 2004, 286(2):H742-748.
44. El-Khatib AS, Moustafa AM, Abdel-Aziz AA, Al-Shabanah OA, El-Kashaf HA: Effects of aminoguanidine and desferrioxamine on some vascular and biochemical changes associated with streptozotocin-induced hyperglycaemia in rats. Pharmacol Res 2001, 43(3):233-240.
45. Dewhurst M, Stevens EJ, Tomlinson DR: Effects of aminoguanidine and N(G)-nitro-L-arginine methyl ester on vascular responses of aorta and lungs from streptozotocin-diabetic rats. Prostaglandins Leukot Essent Fatty Acids 1997, 56(4):317-324.

Publish with BioMed Central and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK

Your research papers will be:
• available free of charge to the entire biomedical community
• peer reviewed and published immediately upon acceptance
• cited in PubMed and archived on PubMed Central
• yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp